[email protected]/(408) 457-3700

About Fe3

25 million people in the US – including 14M women – have mild to moderate anemia. These patients require 20 to 100 mgs/month of iron. While diet can help improve iron levels, in most cases, an additional therapy is needed to bring iron levels to acceptable levels. Oral iron therapy is the current standard of care, yet nearly half of patients have mild to severe gastro intestinal side effects including constipation, nausea, and diarrhea. As a result, many patients do not comply with their therapy and therefore are not receiving sufficient levels of iron. Fe3 is targeting the millions of patients who cannot tolerate oral iron, and also are not candidates for IV iron.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Location:
San Antonio, San Jose, San Francisco Bay Area
Markets:
Medical Devices
Therapeutic Areas:
Hematology, Other